A cheap drug used by longevity enthusiasts may have a surprising impact on exercise

Subscribe to The Post Most newsletter for the most important and interesting stories from The Washington Post. A drug taken ...
The Eastern Herald

Rapamycin Backfires: Anti-Aging Drug May Undermine Exercise Gains, Study Finds

A new study reveals rapamycin may undermine exercise benefits, challenging its hype as a longevity breakthrough.
Hosted on MSN

Fighting cancer cachexia with nutrition and care

Cancer cachexia robs patients of weight, muscle, and strength, undermining treatment success and quality of life. Experts now advocate for a multimodal approach—combining nutrition, exercise, and ...
Nature

Clues to why the weight-loss condition cachexia arises when cancer occurs

Kerstin Haase is in the Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London WC1E 6DD, UK. Mariam Jamal-Hanjani is in the Cancer Research UK Lung ...
Clinical Trials Arena on MSN

CatalYm doses first patient in Phase II/III VINCIT trial

The trial plans to enrol approximately 518 participants.
Business Wire

CatalYm Highlights Visugromab’s Potential to Treat Cachexia in Cancer Patients at International SCWD Conference

MUNICH--(BUSINESS WIRE)--CatalYm today announced new findings from its ongoing Phase 1/2a study as well as preclinical research, highlighting the therapeutic potential of its lead drug candidate, ...
Medical Dialogues

HIIT Effective in Preserving Physical Function and Preventing Sarcopenia in Older Adults: Study

A large-scale, 5-year clinical trial from the Generation 100 study in Norway has found that high-intensity interval training ...
Cure Today

Open-Label Extension of Ponsegromab Shows Efficacy in Cancer-Associated Cachexia

Ponsegromab treatment led to sustained weight gain and GDF-15 suppression over 64 weeks in cancer-associated cachexia patients. Patients initially on placebo gained weight after switching to ...